HER2+ breast cancer

BioNTech challenges AstraZeneca with breast cancer precision drug trial
Reuters
Mon, 01/22/24 - 11:15 am
BioNTech
Duality Biologics
clinical trials
breast cancer
AstraZeneca
Daiichi Sankyo
HER2+ breast cancer
Seagen seeks new approval for Tukysa in HER2+ breast cancer
Clinical Trials Arena
Mon, 12/18/23 - 11:32 am
Seagen
Tukysa
breast cancer
HER2+ breast cancer
FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer
Contract Pharma
Thu, 05/5/22 - 10:40 am
AstraZeneca
Daiichi Sankyo
Enhertu
FDA
HER2+ breast cancer
breast cancer
Here's Why MacroGenics Jumped 156.6% in the First Half of 2020
Motley Fool
Thu, 07/9/20 - 10:29 pm
Macrogenics
HER2+ breast cancer
margetuximab
FDA
Roche Gets FDA OK for Injectable Version of Breast Cancer Drug
Xconomy
Mon, 06/29/20 - 11:59 pm
Roche
HER2+ breast cancer
FDA
Phesgo
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Fri, 12/13/19 - 12:20 pm
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
Fierce Biotech
Wed, 12/11/19 - 10:27 am
Seattle Genetics
breast cancer
tucatinib
HER2+ breast cancer
SABCS
Seattle Genetics' breast cancer drug hits mark in pivotal trial
Fierce Biotech
Mon, 10/21/19 - 10:03 am
Seattle Genetics
clinical trials
HER2+ breast cancer
tucatinib
TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients
Yahoo
Tue, 06/23/15 - 10:53 am
TapImmune
HER2+ breast cancer
breast cancer
HER2/neu
vaccines